{"id":9771,"date":"2018-03-08T08:37:10","date_gmt":"2018-03-08T13:37:10","guid":{"rendered":"https:\/\/medicarereport.org\/?p=9771"},"modified":"2018-03-08T08:37:10","modified_gmt":"2018-03-08T13:37:10","slug":"gottlieb-condemns-rigged-payment-scheme-for-biosimilar-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=9771","title":{"rendered":"Gottlieb condemns \u2018rigged payment scheme\u2019 for biosimilar drugs"},"content":{"rendered":"<p>(By Ike Swetlitz for ST<em>A<\/em>T)<\/p>\n<p class=\"big-cap-wrap danger-zone\"><span class=\"big-cap\">WASHINGTON \u2014 Food and Drug Administration Commissioner Scott Gottlieb said that it\u2019s not his agency\u2019s job to regulate drug prices \u2014 but on Wednesday morning, he used his bully pulpit to condemn a \u201crigged payment scheme\u201d that he said he fears is keeping some generic drugs out of the market. <a href=\"https:\/\/www.statnews.com\/2018\/03\/07\/gottlieb-payment-biosimilar-drugs\/?utm_source=STAT+Newsletters&amp;utm_campaign=d7644c92ef-Pharmalot&amp;utm_medium=email&amp;utm_term=0_8cab1d7961-d7644c92ef-149624405\">Continue reading article here&#8230;<\/a><\/span><\/p>\n<p class=\"big-cap-wrap danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Ike Swetlitz for STAT) WASHINGTON \u2014 Food and Drug Administration Commissioner Scott Gottlieb said that it\u2019s not his agency\u2019s<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,21,15],"tags":[],"class_list":["post-9771","post","type-post","status-publish","format-standard","hentry","category-fda","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/9771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9771"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/9771\/revisions"}],"predecessor-version":[{"id":9772,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/9771\/revisions\/9772"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}